<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Left ventricular noncompaction (LVNC) is a rare <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> with potentially serious outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>It results in multiple and excessive trabeculations, deep intertrabecular recesses, and a thickened ventricular myocardium with two distinct layers, compacted and noncompacted </plain></SENT>
<SENT sid="2" pm="."><plain>The condition is most commonly congenital; however, acquired forms have also been described </plain></SENT>
<SENT sid="3" pm="."><plain>A recent report of LVNC detected in a β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> twin suggested an association with <z:e sem="disease" ids="C1504347" disease_type="Disease or Syndrome" abbrv="">cardiac siderosis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In a cross-sectional study of 135 transfusion-dependent patients with β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> (130 major and 5 intermedia, mean age 29.6 ± 7.7 years, 49.6% males) presenting for cardiac iron assessment by magnetic resonance imaging (MRI), we evaluated the prevalence and risk factors for LVNC </plain></SENT>
<SENT sid="5" pm="."><plain>None of the patients had neuromuscular or <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Eighteen patients (13.3%; 95% confidence interval [CI] = 8.6-20.1) fulfilled the preassigned strict criteria for LVNC on cardiac MRI </plain></SENT>
<SENT sid="7" pm="."><plain>There were no statistically significant differences between patients with and without LVNC with respect to demographics; <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels; splenectomy status; systemic, hepatic, and cardiac <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> indices; <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e> and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> studies; or iron <z:chebi fb="0" ids="38161">chelator</z:chebi> type </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with LVNC were more likely to have <z:hpo ids='HP_0001635'>heart failure</z:hpo> (adjusted odds ratio = 1.77; 95% CI = 0.29-10.89); although with high uncertainty </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> have a higher prevalence of LVNC than <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
<SENT sid="10" pm="."><plain>As this finding could not be explained by conventional risk factors in this patient population, further investigation of the underlying mechanisms of LVNC is warranted </plain></SENT>
<SENT sid="11" pm="."><plain>This remains crucial for an entity with adverse cardiac outcomes, especially in patients with β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> where <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> remains a primary cause of mortality </plain></SENT>
<SENT sid="12" pm="."><plain>Am </plain></SENT>
<SENT sid="13" pm="."><plain>J </plain></SENT>
<SENT sid="14" pm="."><plain>Hematol., 2012. © 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>